Abbott said that greater than 90 percent of the issued and outstanding shares of preferred stock had been tendered as of Sept. 15.
The firm extended its cash tender offer for all outstanding shares of Alere's Series B convertible perpetual preferred stock until the end of the day on Sept. 15.
The lab is a major genetic testing supplier to all 27 of Australia's major beef cattle associations, and provides services for other farm animals.
The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.
Thermo Fisher has acquired the contract development and manufacturing organization for $35 per share in cash.
The firm said it may use the loans to finance its $1.3 billion acquisition of Euroimmun Medical Laboratory Diagnostics.
The firm missed analysts' expectations on both the top and bottom lines, despite a reported 20 percent increase in clinical services revenues during the quarter.
The company may use the proceeds of the loans to help fund the $7.2 billion acquisition of Patheon. The loan facility follows a $1.5 billion senior notes offering by Thermo Fisher last week.
The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.
The company is aiming to raise $1.5 billion through the issuance of 3.2% senior notes due 2027 and 4.1% senior notes due 2047.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.